CN Patent

CN113811298B — 用于联合治疗小细胞肺癌的喹啉衍生物

Assigned to Chia Tai Tianqing Pharmaceutical Group Co Ltd · Expires 2023-08-01 · 3y expired

What this patent protects

一种用于治疗小细胞肺癌的联用药物组合物，其包括：(i)化合物I或其药学上可接受的盐；和(ii)至少一种第二治疗药物，化合物I的化学名为1‑[[[4‑(4‑氟‑2‑甲基‑1H‑吲哚‑5‑基)氧基‑6‑甲氧基喹啉‑7‑基]氧基]甲基]环丙胺。

USPTO Abstract

一种用于治疗小细胞肺癌的联用药物组合物，其包括：(i)化合物I或其药学上可接受的盐；和(ii)至少一种第二治疗药物，化合物I的化学名为1‑[[[4‑(4‑氟‑2‑甲基‑1H‑吲哚‑5‑基)氧基‑6‑甲氧基喹啉‑7‑基]氧基]甲基]环丙胺。

Drugs covered by this patent

tivozanib-hydrochloride (TIVOZANIB HYDROCHLORIDE)

Patent Metadata

Patent number: CN113811298B
Jurisdiction: CN
Classification: —
Expires: 2023-08-01
Drug substance claim: No
Drug product claim: No
Assignee: Chia Tai Tianqing Pharmaceutical Group Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.